May 13, 2020 / 12:00PM GMT
Operator
Ladies and gentlemen, thank you for standing by, and welcome to the Bristol-Myers Squibb Investor Conference Call. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions)
I would now like to hand the conference over to your speaker today, Mr. Tim Power, Vice President, Investor Relations. Thank you. Please go ahead, sir.
Timothy Power - Bristol-Myers Squibb Company - VP & Head of IR
Thank you, Daniel, and good morning, everyone. Thanks for joining us for our call this morning. I'm joined today for today's call by Giovanni Caforio, our Chairman and Chief Executive Officer; by Samit Hirawat our Chief Medical Officer and Head of Global Drug Development. Giovanni will briefly open the call in a minute and then hand over to Samit for opening remarks. Also joining me today along with Giovanni and Samit for the Q&A section is Nadim Ahmed, President of Hematology.
Before we get started, let me read our forward-looking statements. During this call, we make statements about the company's
Bristol-Myers Squibb Co and bluebird bio Inc to Provide Regulatory Update on Idecabtagene Vicleucel - Conference Call Transcript
May 13, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers